Battle of Dividends: Costco vs Whole Foods

Battle of Dividends: Costco vs Whole Foods

They’re both outstanding retailers — especially in their respective niches. Costco Wholesale (NASDAQ:COST) is second to none in both scale and operational efficiency when it comes to the warehouse club retail model, which it pioneered in the first place. And Whole Foods (NASDAQ:WFM) is the largest grocer of natural and organic foods in the U.S., → Read More

Lockheed Martin Earnings: Here's the 1 Number That Matters Most

Lockheed Martin Earnings: Here's the 1 Number That Matters Most

Shares of Lockheed Martin (NYSE:LMT) stock dropped 3.5% in the two days following its Tuesday earnings report, before stabilizing and then beginning to climb back out of their hole. As of today’s share price of $252.50, the stock is selling for just 13.9 times earnings — a seemingly low price to pay for part ownership → Read More

Scotch Sales Drive Diageo plc's Growth

Scotch Sales Drive Diageo plc's Growth

The global spirits industry continues to be strong, driving results for Diageo plc (NYSE:DEO) higher in the first half of fiscal 2017, for which it reported results Thursday. Currency changes helped growth (and keep in mind that the numbers below are in Diageo’s reported British pounds and pence), but organic trends for the business are → Read More

Is GlaxoSmithKline's Dividend Sustainable?

Is GlaxoSmithKline's Dividend Sustainable?

British drugmaker GlaxoSmithKline plc (NYSE:GSK) is one of the top-yielding dividend stocks in the medical sector. Company management has committed to paying a quarterly dividend through 2017 that amounts to a yield of 4.7% at today’s exchange rate. A rich payout like that will attract the attention of dividend investors — but how safe is that → Read More

Here's the Reason Behind TESARO Inc.'s Sudden 12% Move Higher

Here's the Reason Behind TESARO Inc.'s Sudden 12% Move Higher

What happened Shares of TESARO (NASDAQ:TSRO), a biopharmaceutical company that’s primarily focused on developing therapies to treat cancer, surged as much as 12% during Thursday’s trading session after reports surfaced that French drugmaker Sanofi (NYSE:SNY) may be interested in acquiring it. So what Sanofi has been on an acquisition hunt for quite some time, and → Read More

Jagged Peak Energy IPO: What Investors Need to Know

Jagged Peak Energy IPO: What Investors Need to Know

The Permian Basin, which sprawls across Texas and a piece of New Mexico, is the hot U.S. oil and gas play now. It’s “stacked,” meaning that there are multiple oil-rich rock layers piled on top of one another. Its acreage is soaked with black gold, making it cost-effective even in these times of relatively depressed oil prices.  → Read More

Qualcomm's FTC Defender Just Got a Major Promotion

Qualcomm's FTC Defender Just Got a Major Promotion

A little over a week after the U.S. Federal Trade Commission lodged an antitrust complaint against Qualcomm (NASDAQ:QCOM), the likelihood of the mobile chip giant facing harsh regulatory backlash just got a little smaller. President Trump has just appointed Republican FTC Commissioner Maureen Ohlhausen as acting chairwoman of the FTC. While some of Trump’s nominees → Read More

CARBO Ceramics Shares Are Up a Staggering 30% Today After Strong Earnings

CARBO Ceramics Shares Are Up a Staggering 30% Today After Strong Earnings

What happened Shares of CARBO Ceramics (NYSE:CRR) were up 30.8% as of 2:00 p.m. EST today after the company reported earnings that showed a strong uptick in sequential revenue. So what The frack sand has been a tough one over the past two years. After going gangbusters in 2014 with every producer out there wanting → Read More

Is TransCanada Corporation's Stock a Buy Now That the Keystone XL Pipeline Is Back in Play?

Is TransCanada Corporation's Stock a Buy Now That the Keystone XL Pipeline Is Back in Play?

President Donald Trump recently signed executive orders aimed at restarting stalled oil pipeline projects, including a request that TransCanada (NYSE:TRP) reapply for approval of its controversial Keystone XL pipeline. While the president’s invitation has the Canadian oil pipeline giant reevaluating the project, it does not guarantee the project will move forward. That’s why investors shouldn’t → Read More

Vertex Pharmaceuticals Incorporated Turns a Profit

Vertex Pharmaceuticals Incorporated Turns a Profit

The fourth-quarter revenue numbers for Vertex Pharmaceuticals (NASDAQ:VRTX) weren’t a big surprise since the biotech had previously announced preliminary results earlier this month at the JP Morgan Healthcare Conference. Nevertheless, Wednesday’s earnings release contained details about the bottom line — a profit, no less — and updates on its pipeline of drugs. Vertex Pharmaceuticals results: → Read More

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.